Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development
Alice Egerton, Anthony A. Grace, James Stone, et al.
Schizophrenia Research (2020) Vol. 223, pp. 59-70
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Hidden Role of Gut Microbiome Dysbiosis in Schizophrenia: Antipsychotics or Psychobiotics as Therapeutics?
Nayla Munawar, Khansa Ahsan, Khalid Muhammad, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7671-7671
Open Access | Times Cited: 68
N-Acetyl-Aspartyl-Glutamate in Brain Health and Disease
Cecilie Morland, Kaja Nordengen
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1268-1268
Open Access | Times Cited: 58
Biological hypotheses, risk factors, and biomarkers of schizophrenia
Zdeněk Fišar
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2022) Vol. 120, pp. 110626-110626
Closed Access | Times Cited: 57
Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis
Kate Merritt, Robert A. McCutcheon, André Alemán, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 5, pp. 2039-2048
Open Access | Times Cited: 37
Biological subtyping of psychiatric syndromes as a pathway for advances in drug discovery and personalized medicine
Wenjing Zhang, John A. Sweeney, Jeffrey R. Bishop, et al.
Nature Mental Health (2023) Vol. 1, Iss. 2, pp. 88-99
Closed Access | Times Cited: 29
Glutamatergic neurotransmission: A potential pharmacotherapeutic target for the treatment of cognitive disorders
Pratik Chakraborty, Abhijit Dey, Abilash Valsala Gopalakrishnan, et al.
Ageing Research Reviews (2023) Vol. 85, pp. 101838-101838
Closed Access | Times Cited: 23
Involvement of the Expression of G Protein-Coupled Receptors in Schizophrenia
Raluka Kalinovic, Andrei Pascariu, Gabriela Vlad, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 1, pp. 85-85
Open Access | Times Cited: 9
New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists
Aineng Peng, Chai Jian-bo, Haiyuan Wu, et al.
Neuropsychiatric Disease and Treatment (2024) Vol. Volume 20, pp. 607-620
Open Access | Times Cited: 8
Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics
Andrea de Bartolomeis, Licia Vellucci, Mark C. Austin, et al.
Biomolecules (2022) Vol. 12, Iss. 7, pp. 909-909
Open Access | Times Cited: 29
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 17
GABAergic System Dysfunction and Challenges in Schizophrenia Research
Muhammad Jahangir, Jiansong Zhou, Bing Lang, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 34
Bridging the Gap? Altered Thalamocortical Connectivity in Psychotic and Psychedelic States
Mihai Avram, Helena Rogg, Αλεξάνδρα Κορδά, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 32
Second-Generation Antipsychotics’ Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders
Michele Fabrazzo, Salvatore Cipolla, Alessio Camerlengo, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 15, pp. 4530-4530
Open Access | Times Cited: 27
Neurofunctional correlates of glutamate and GABA imbalance in psychosis: A systematic review
Uzma Zahid, Ellis Chika Onwordi, Emily Hedges, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 144, pp. 105010-105010
Open Access | Times Cited: 23
Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia
David Olivares-Berjaga, Albert Martínez-Pinteño, Natàlia Rodríguez, et al.
Translational Psychiatry (2025) Vol. 15, Iss. 1
Open Access
Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients
Sergej Nadalin, Ivan Ljoka, Aleksandar Savić, et al.
Prostaglandins Leukotrienes and Essential Fatty Acids (2025), pp. 102665-102665
Closed Access
The substantia nigra in the pathology of schizophrenia: A review on post-mortem and molecular imaging findings
Carmen F.M. van Hooijdonk, Marieke van der Pluijm, Iris Bosch, et al.
European Neuropsychopharmacology (2023) Vol. 68, pp. 57-77
Open Access | Times Cited: 12
Histamine H 2 receptor deficit in glutamatergic neurons contributes to the pathogenesis of schizophrenia
Qianyi Ma, Lei Jiang, Han Chen, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 9
Open Access | Times Cited: 12
Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia
Ravi Anand, Alessio Turolla, Giovanni Chinellato, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 8, pp. 523-528
Open Access | Times Cited: 11
Symptomatic versus disease‐modifying effects of psychiatric drugs
S. Nassir Ghaemi
Acta Psychiatrica Scandinavica (2022) Vol. 146, Iss. 3, pp. 251-257
Closed Access | Times Cited: 17
Psychedelics action and schizophrenia
Marzena Maćkowiak
Pharmacological Reports (2023) Vol. 75, Iss. 6, pp. 1350-1361
Open Access | Times Cited: 10
Molecular Abnormalities in BTBR Mice and Their Relevance to Schizophrenia and Autism Spectrum Disorders: An Overview of Transcriptomic and Proteomic Studies
Polina E. Kisaretova, А. С. Цыбко, Natalia P. Bondar, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 289-289
Open Access | Times Cited: 9
Ion Channel Disturbances in Migraine Headache: Exploring the Potential Role of the Kynurenine System in the Context of the Trigeminovascular System
Eleonóra Spekker, Gábor Nagy-Grócz, László Vécsei
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16574-16574
Open Access | Times Cited: 9
Efficacy and safety of add-on sodium benzoate, a D-amino acid oxidase inhibitor, in treatment of schizophrenia: A systematic review and meta-analysis
Jyothsna Chinnapura Seetharam, Rituparna Maiti, Archana Mishra, et al.
Asian Journal of Psychiatry (2021) Vol. 68, pp. 102947-102947
Closed Access | Times Cited: 18
Ketamine as a pharmacological tool for the preclinical study of memory deficit in schizophrenia
José Eduardo Suárez Santiago, Gabriel Roldán, Ofir Picazo
Behavioural Pharmacology (2022) Vol. 34, Iss. 2-3, pp. 80-91
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top